Yuan J, Shen C, Wang C, et al. Assessment of Physician's Knowledge of Potential Drug-Drug Interactions: An Online Survey in China. Front. Med. 2021;8:650369. doi: 10.3389/fmed.2021.650369
Abubakar AR, Chedi BA, Mohammed KG, et al. Drug interaction and its implication in clinical practice and personalized medicine. Natl J Physiol Pharm Pharmacol. 2015;5:343-349.
Gonzaga de Andrade Santos TN, Mendonça da Cruz Macieira G, Cardoso Sodré Alves BM, et al. Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis. PLoS One. 2020 Jul 1;15(7):e0235353. doi: 10.1371/journal.pone.0235353.
Peng Y, Cheng Z, Xie F. Evaluation of pharmacokinetic drug-drug interactions: A review of the mechanisms, in vitro and in silico approaches. Metabolites. 2021 Jan; 11(2): 75. doi:10.3390/metabo11020075
de Oliveira LM, Diel JDAC, Nunes A, et al. Prevalence of drug interactions in hospitalised elderly patients: a systematic review. Eur J Hosp Pharm. 2021 Jan; 28(1): 4-9. doi:10.1136/ejhpharm-2019-002111
Greenblatt DJ. Mechanisms and consequences of drug-drug interactions. Clin Pharmacol Drug Dev. 2017 Mar; 6(2): 118-124. doi:10.1002/cpdd.339
Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J. 2020 Jun; 20(3): 355-366. doi:10.1038/s41397-019-0122-0
Hochman J, Tang C, Prueksaritanont T. Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective. J Pharm Sci. 2015 Mar; 104(3): 916-929. doi:10.1002/jps.24306
Kamel A, Harriman S. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov Today Technol. 2013; 10(1): e177-e189. doi:10.1016/j.ddtec.2012.09.011
Ivanyuk A, Livio F, Biollaz J, et al. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017 Aug; 56(8): 825-892. doi:10.1007/s40262-017-0506-8
Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther. 2019 Jun; 105(6): 1395-1406. doi:10.1002/cpt.1434
Saputra EC, Huang L, Chen Y, et al. Combination therapy and the evolution of resistance: The theoretical merits of synergism and antagonism in cancer. Cancer Res. 2018 May; 78(9): 2419-2431. doi:10.1158/0008-5472.CAN-17-1201
European Medicines Agency. Guideline on the investigation of drug interactions. [Internet]. CPMP/EWP/560/95/Rev. 1 Corr. 2 [last updated 2015 Jun 03, cited 2023 Jul 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. [Internet]. [last updated 2020 Jan 23, cited 2023 Jul 20]. Available from: https://www.fda.gov/media/134581/download
Food and Drug Administration, Center for Drug Evaluation and Research (CDER). In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. [Internet]. [last updated 2020 Jan 23, cited 2023 Jul 20]. Available from: https://www.fda.gov/media/134582/download
Song Y, Li C, Liu G, et al. Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes. Clin Pharmacokinet. 2021 May; 60(5): 585-601. doi:10.1007/s40262-021-01001-5
Янева И, Балабански В, Белчева В, Каранешева Т. Взаимодействия между растителни и лекарствени продукти на ниво цитохром Р 450. Годишник по болнична фармация. 2020 Окт; 6(1):33-41
Deodhar M, Al Rihani SB, Arwood MJ, et al. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics. 2020 Sep; 12(9): 846. doi:10.3390/pharmaceutics12090846
Zhang L, Zhang YD, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009 Jun; 11(2): 300-306. doi:10.1208/s12248-009-9106-3
Mohutsky MA, Romeike A, Meador V, et al. Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. Toxicol Pathol. 2010 Aug; 38(5): 799-809. doi:10.1177/0192623310375099
Graziano S, Montana A, Zaami S, et al. Sildenafil-associated hepatoxicity: a review of the literature. Eur Rev Med Pharmacol Sci. 2017 Mar; 21(1 Suppl): 17-22.
Lepist EI, Ray AS. Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins. Expert Opin Drug Metab Toxicol. 2017 Oct; 13(10): 1075-1087.
doi:10.1080/17425255.2017.1372425
Morris ME, Rodriguez-Cruz V, Felmlee MA. SLC and ABC transporters: Expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers. AAPS J. 2017 Sep; 19(5): 1317-1331. doi:10.1208/s12248-017-0110-8
Ali Y, Shams T, Wang K, et al. The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions. Chin Med. 2020 Jul; 15: 71. doi:10.1186/s13020-020-00351-9
Knop J, Misaka S, Singer K, et al. Inhibitory effects of Green tea and (-)-epigallocatechin gallate on transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-glycoprotein. PLoS One. 2015 Oct; 10(10): e0139370. doi:10.1371/journal.pone.0139370
Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist. 2021 Aug; 4: 784-804. doi:10.20517/cdr.2021.19
Li Y, Meng Q, Yang M, et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019 Nov; 9(6): 1113-1144. doi:10.1016/j.apsb.2019.10.001
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008; (182): 335-360. doi:10.1007/978-3-540-74806-9_16
Carpenter M, Berry H, Pelletier AL. Clinically relevant drug-drug interactions in primary care. American family physician. 2019 May; 99(9): 558–564.
Изпълнителна Агенция по Лекарствата. Кратка характеристика на продукта. [Internet]. [cited 2023 Jul 22] Available from: https://www.bda.bg/images/stories/documents/bdias/2020-06-22-119759.pdf
Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar; 11: 449-467. doi:10.2147/TCRM.S80437
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May; 149(3): 139-152. doi:10.1177/1715163516641136
Wang Y, Bahar MA, Jansen AME, et al. Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. J Antimicrob Chemother. 2019 Oct; 74(10): 2848-2864. doi:10.1093/jac/dkz221
Das B, Ramasubbu SK, Kumar B, et al. Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients. J Family Med Prim Care. 2020 Dec; 9(12): 6023-6040. doi:10.4103/jfmpc.jfmpc_1060_20
Foy M, Sperati CJ, Lucas GM, et al. Drug interactions and antiretroviral drug monitoring. Curr HIV/AIDS Rep. 2014 Sep; 11(3): 212-222. doi:10.1007/s11904-014-0212-1
European Medicines Agency. Summary of product characteristics. [Internet]. [cited 2023 Jul 22] Available from: https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_en.pdf
Fernandes BD, Almeida PHRF, Foppa AA, et al. Pharmacist-led medication reconciliation at patient discharge: A scoping review. Res Social Adm Pharm. 2020 May;16(5):605-613. doi: 10.1016/j.sapharm.2019.08.001.
Barnsteiner JH. Medication Reconciliation. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Apr. Chapter 38. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2648/
EAHP. European Statements of Hospital Pharmacy. Last update: 26 November 2021. Accessed on: 15 Jul 2023. Available from: https://www.eahp.eu/sites/default/files/bulgarian.pdf
Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016 Feb 23;6(2):e010003. doi: 10.1136/bmjopen-2015-010003.
Missiakos O, Baysari MT, Day RO. Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approach. Int J Med Inform. 2015 Aug;84(8):595-600. doi: 10.1016/j.ijmedinf.2015.04.001.
Han K, Cao P, Wang Y, et al. A Review of Approaches for Predicting Drug-Drug Interactions Based on Machine Learning. Front Pharmacol. 2022 Jan 28;12:814858. doi: 10.3389/fphar.2021.814858.
Bach QN, Peasah SK, Barber E. Review of the Role of the Pharmacist in Reducing Hospital Readmissions. J Pharm Pract. 2019 Dec;32(6):617-624. doi: 10.1177/0897190018765500.
Email this article (Login required) 
